May 1 (Reuters) - GSK plc:
* GSK PLC - 1ST QUARTER RESULTS
* GSK: EXPECT 2024 TURNOVER GROWTH TOWARDS UPPER PART OF 5% TO 7% RANGE
* GSK: IN QUARTER VACCINES SALES +16%, +22% EX COVID. SHINGRIX £0.9 BILLION +18%, AREXVY £0.2 BILLION
* GSK SEES 2024 CORE EPS GROWTH OF 8% TO 10%
* GSK SEES 2024 CORE OPERATING PROFIT GROWTH OF 9% TO 11%
* GSK: DIVIDEND DECLARED OF 15P FOR Q1 2024; 60P EXPECTED FOR FULL YEAR 2024
* GSK: BENEFITTED IN QUARTER FROM SUCCESSFUL ZEJULA ROYALTY DISPUTE APPEAL, AND WE ALSO EXPECT ROYALTY INCOME TO BE SLIGHTLY HIGHER FOR FULL YEAR
* GSK: EXPECTS FIRST HALF 2024 SALES GROWTH TO BE HIGHER THAN SECOND HALF 2024 DUE TO COMPARATOR TO H2 2023
* GSK: EXPECT MAJORITY OF SHINGRIX SALES IN CHINA IN TO BE IN FIRST HALF 2024
* GSK: H2, COMPARED TO PRIOR YEAR, EXPECTED TO BE INFLUENCED BY 2023 LAUNCH DYNAMICS AND INITIAL CHANNEL INVENTORY BUILD ATTRIBUTABLE TO AREXVY
* GSK: FOR FULL YEAR 2024, GSK DOES NOT ANTICIPATE ANY FURTHER COVID-19 PANDEMIC-RELATED SALES OR OPERATING PROFIT
* GSK: SIGNIFICANT LEGAL CHARGES IN QUARTER PRIMARILY REFLECTED PROSPECTIVE LEGAL COSTS FOR DEFENCE OF LITIGATION RELATING TO ZANTAC Further company coverage: